<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anticardiolipin antibodies are produced both in patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) and in patients with <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, but <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity has been reported only for the former group </plain></SENT>
<SENT sid="1" pm="."><plain>To understand these differences, affinity-purified immunoglobulin G anticardiolipin antibodies from APS (n = 11) and <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> (n = 5) patients were compared </plain></SENT>
<SENT sid="2" pm="."><plain>Only the antibodies from the APS group inhibited prothrombin conversion to thrombin and cross-reacted with phosphatidylserine </plain></SENT>
<SENT sid="3" pm="."><plain>These findings may enable better definition of the <z:chebi fb="0" ids="16247">phospholipid</z:chebi> <z:chebi fb="0" ids="53000">epitopes</z:chebi> involved in the hemostatic abnormalities of APS </plain></SENT>
</text></document>